Yasemin COŞGUN, Dilek MENEMENLİOĞLU, Ahmet SAFRAN, Burcu GÜRER GIRAY, Esma ÖDEVLI, Seda GÜDÜL HAVUZ, Erkan ÖZMEN, Ali Korhan SIĞ, Ahmet AYDEMİR, Dilek YAĞCI ÇAĞLAYIK, Gülay KORUKLUOĞLU, Seher TOPLUOĞLU, Selçuk KILIÇ

Comparison of laboratory findings in PCR-positive and IgM-positive Crimean-Congo hemorrhagic fever cases

Objective: Crimean-Congo hemorrhagic fever (CCHF) develops in one-fifth of the individuals infected with the CCHF virus. The clinical course progresses very rapidly and can result in death within 7-10 days. The aim of this study is to determine whether there is a difference between the PCR-positive period and the IgM-positive period in terms of laboratory findings and to investigate the effect of the difference, if any, on the course of the disease. Methods: Results of 5131 serum samples submitted to public health laboratories for the diagnosis of CCHF between January 1, 2015, and December 31, 2017, were included in the study. PCR and IFA IgM test results of these samples and other laboratory findings of the patients were evaluated. Findings were compared between fatal and non-fatal cases. Results: When laboratory results of the PCR-positive period and IgM-positive period were compared, there was a statistically significant difference in terms of creatinine value, presence of thrombocytopenia (

PCR-pozitif ve IgM-pozitif Kırım-Kongo kanamalı ateşi olgularında laboratuvar bulgularının karşılaştırılması

Amaç: Kırım-Kongo kanamalı ateşi (KKKA) hastalığı, KKKA virüsü ile enfekte bireylerin beşte birinde meydana gelir. Hastalığın klinik seyri çok hızlı ilerleyerek 7-10 gün içinde ölümle sonuçlanabilmektedir. Bu çalışmanın amacı, laboratuvar bulguları açısından PCR-pozitif dönem ile IgM-pozitif dönem arasında fark olup olmadığını belirlemek, varsa farklılığın hastalığın seyrine etkisini araştırmaktır. Yöntem: 1 Ocak 2015 - 31 Aralık 2017 tarihleri arasında KKKA tanısı amacıyla halk sağlığı laboratuvarlarına gönderilen 5131 serum örneği çalışmaya dahil edildi. Bu örneklerin PCR ve IFA-IgM testi sonuçları ve hastaların diğer laboratuvar bulguları değerlendirildi. Yaşamını sürdüren ve ölümcül seyreden hastaların bulguları karşılaştırıldı. Bulgular: PCR-pozitif dönem ve IgM-pozitif döneme ait laboratuvar sonuçları karşılaştırıldığında, kreatinin değeri, trombositopeni varlığı (

PDF

___

1. Ergönül O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006;6:203-14.
2. Akın L. Kırım-Kongo kanamalı ateşi. Hacettepe Tıp Dergisi 2008;39:134-43.
3. Ergönül Ö. Kırım-Kongo kanamalı ateşi. ANKEM Derg 2009;23:234-40.
4. https://hsgm.saglik.gov.tr/tr/zoonotikvektorelkkka (Accessed 08.09.2019).
5. Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M, Karakus G, et al. Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patients with Crimean-Congo hemorrhagic fever. BMC Infect Dis. 2014;28:14:416.
6. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Turkish CCHF Study Group. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol. 2005;54:385–9.
7. Çevik MA. Kırım-Kongo hemorajik ateşi: klinik özellikler. KLİMİK Derg 2004;17:59-61.
8. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, et al. Crimean-Congo Hemorrhagic Fever in Turkey. Emerg Infect Dis. 2004;10;1379-84.
9. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis. 2003;36:1613-8.
10. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989;11:794–800.
11. Bakir M, Gozel MG, Koksal I, Asik Z, Gunal O, Yılmaz H, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015;34:325-30.
12. Dokuzoguz B, Celikbas AK, Gök ŞE, Baykam N, Eroglu MN, Ergönül Ö. Severity Scoring Index for Crimean-Congo Hemorrhagic Fever and the Impact of Ribavirin and Corticosteroids on Fatality. Clin Infect Dis. 2013;57:1270–4.
13. Chinikar S, Goya MM, Shirzadi MR, Ghiasi SM, Mirahmadi R, Haeri A, et al. Surveillance and laboratory detection system of Crimean-Congo haemorrhagic fever in Iran. Transbound Emerg Dis. 2008;55:200-4.
14. Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res. 2011;90:85- 92.
15. Keshtkar-Jahromi M, Sajadi MM, Ansari H, Mardani M, Holakouie-Naieni K. Crimean-Congo hemorrhagic fever in Iran. Antiviral Res. 2013;100:20–8.
16. Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989;11:801–6.
17. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN--time for reappraisal. Crit Care. 2009;13(3):211. doi:10.1186/cc7759.
18. Sumer A. The evaluation of the patients who were admitted to the emergency department of Kaş State Hospital because of tick biting. Kafkas Üniv Vet Fak Derg 2010;16:49–53.
19. Bilgin G, Ataman Hatipoglu C, Altun S, Bulut C, Kinikli S, Demiröz AP. An investigation of pulmonary findings of Crimean–Congo haemorrhagic fever patients. Send to Turk J Med Sci. 2014;44:162-7.
20. Hasanoglu I, Guner R, Carhan A, Kocak Tufan Z, Yagci-Caglayik D, Guven T, et al. Crucial parameter of the outcome in Crimean Congo hemorrhagic fever: Viral load. J Clin Virol. 2016;75:42-6.
21. Inci A. The Prevalence of Crimean-Congo Haemorrhagic Fever and the Significance of Geographic, Climatic Features, and Tick Abundance, Klimik Derg. 2015;28: 68-71.
22. Durrani AB, Shaikh M, Khan Z. Congo crimean hemorrhagic Fever in balochistan. J Coll Physicians Surg Pak. 2007;17:543-5.
23. Cevik MA, Erbay A, Bodur H, Gülderen E, Baştuğ A, Kubar A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008; 12:374–9.
24. Yilmaz G, Koksal I, Topbas M, Yilmaz H, Aksoy F. The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: severity prediction criteria. J Clin Virol. 2010;47:361–5.
25. Tasdelen Fisgin N, Tanyel E, Doganci L, Tulek. Risk factors for fatality in patients with Crimean-Congo haemorrhagic fever. Trop Doct. 2009;39:158–60.
26. Onguru P, Dagdas S, Bodur H, Yilmaz M, Akinci E, Eren S, et al. Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. J Clin Lab Anal. 2010;24:163–6.
27. Hatipoglu CA, Bulut C, Yetkin MA, Ertem GT, Erdinc FS, Kilic EK, et al. Evaluation of clinical and laboratory predictors of fatality in patients with Crimean-Congo haemorrhagic fever in a tertiary care hospital in Turkey. Scand J Infect Dis 2010;42:516–1.
28. Kazancioglu S, Akinci E, Baştug A, Kayaaslan B, But A, Aslaner H, et al. Does the course of laboratory parameters help us to predict the outcome of CCHF? Turk J Med Sci. 2016;46:328-34.